Gilead adds to oncology, inflammation portfolio with XinThera acquisition
Michael Vi         
Gilead Sciences (NASDAQ:GILD) has acquired privately held XinThera giving the large biotech a portfolio of preclinical candiates for oncology and inflammatory diseases.
The deal is an all-stock transaction. Financial terms were not revealed.
Gilead (GILD) said the transaction would likely negatively impact its 2023 GAAP and non-GAAP EPS by $0.12 - $0.15.
XinThera has three candidates in the IND-enabling stage, all targeting PARP1. It also has two candidates in the IND-enabling stage targeting MK2.

More on Gilead Sciences

Gilead Sciences: A Mixed First Quarter
Gilead Versus AbbVie: The Better Bet After Q1, 2023 Earnings